Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the appointment of Erik van den Berg as Chief Executive Officer.
Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the appointment of Erik van den Berg as Chief Executive Officer.